Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)”

59 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 59 results

Not applicableStudy completedNCT06072196
What this trial is testing

Learn About Novel Hormonal Therapies in People With Metastatic Castration-Sensitive Prostate Cancer (mCSPC)

Who this might be right for
Prostatic Neoplasms
Pfizer 3,017
Large-scale testing (Phase 3)Study completedNCT04934722
What this trial is testing

Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991)-China Extension

Who this might be right for
Metastatic Hormone-Sensitive Prostate Cancer
Merck Sharp & Dohme LLC 186
Not applicableStudy completedNCT06498921
What this trial is testing

An Observational Study to Learn More About the Use of Darolutamide as a Part of a Combination Therapy in Belgian Men With Metastatic Hormone-Sensitive Prostate Cancer in Routine Medical Care

Who this might be right for
Metastatic Hormone-sensitive Prostate Cancer
Bayer 106
Not applicableActive Not RecruitingNCT06019676
What this trial is testing

Impact of Apalutamide in Metastatic Hormone Sensitive Prostate Cancer Patients

Who this might be right for
Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Royal Marsden NHS Foundation Trust 170
Testing effectiveness (Phase 2)Not Yet RecruitingNCT04925063
What this trial is testing

The Effect of Metformin in Patients With Newly Diagnosed mHSPC

Who this might be right for
Metastatic Prostate Cancer
Sun Yat-sen University 266
Not applicableStudy completedNCT06452212
What this trial is testing

Non-Interventional Study to Establish Consensus on Management of Metastatic Hormone-Sensitive Prostate Cancer Patients

Who this might be right for
Metastatic Hormone-Sensitive Prostate Cancer
Astellas Pharma Korea, Inc. 23
Large-scale testing (Phase 3)Looking for participantsNCT06496581
What this trial is testing

Standard of Care +/- 177Lu-PSMA-617 In de Novo mHSPC Patients With Poor PSA Response (PEACE6-Poor Responders)

Who this might be right for
Prostate Cancer Metastatic
UNICANCER 500
Not applicableUnknownNCT05530395
What this trial is testing

BAseLine TEstosterone as a Prognostic and/or Predictive bioMARKer in mHSPC

Who this might be right for
Prostate Cancer Metastatic
Ignacio Puche Sanz 300
Not applicableLooking for participantsNCT06661122
What this trial is testing

Learn About How Safe Darolutamide is and How Well it Works in Combination With Androgen Deprivation Therapy and Docetaxel in Routine Medical Care for Japanese Men With Low Volume Metastatic Hormone-Sensitive Prostate Cancer

Who this might be right for
Metastatic Hormone-sensitive Prostate Cancer (mHSPC)Low-volume Metastasis
Bayer 100
Very early researchActive Not RecruitingNCT05683964
What this trial is testing

Androgen Receptor Signaling and Prostate-Specific Membrane Antigen Expression

Who this might be right for
Prostate AdenocarcinomaProstate CancerMetastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Beth Israel Deaconess Medical Center 9
Not applicableEnrolling By InvitationNCT06865547
What this trial is testing

ProA Study: ProActive Management Model in Metastatic Hormone Sensitive Prostate Cancer (mHSPC) Treated by Apalutamide

Who this might be right for
Prostate Cancer (Adenocarcinoma)
Yonghong Li 94
Large-scale testing (Phase 3)Looking for participantsNCT05983783
What this trial is testing

Comparing the Efficacy and Safety of Rezvilutamide+ADT+Docetaxel Versus Rezvilutamide +ADT in the mHSPC

Who this might be right for
Metastatic Prostate CancerHormone Sensitive Prostate CancerChemotherapy Effect
The First Affiliated Hospital with Nanjing Medical University 200
Testing effectiveness (Phase 2)Looking for participantsNCT07190300
What this trial is testing

TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

Who this might be right for
Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Novartis Pharmaceuticals 181
Large-scale testing (Phase 3)Looking for participantsNCT05956639
What this trial is testing

Comparing a 6-month vs Long-term Course of Rezvilutamide With ADT Plus Chemotherapy in mHSPC

Who this might be right for
Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
The First Affiliated Hospital with Nanjing Medical University 100
Not applicableLooking for participantsNCT07451002
What this trial is testing

Assess Adherence to Apalutamide in Metastatic Hormone-Sensitive Prostate Cancer Participants in France

Who this might be right for
Prostatic NeoplasmsMetastatic Hormone-sensitive Prostate Cancer
Janssen Cilag S.A.S. 270
Large-scale testing (Phase 3)Active Not RecruitingNCT04720157
What this trial is testing

An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care (SoC), Versus SoC Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)

Who this might be right for
Prostatic Neoplasms
Novartis Pharmaceuticals 1,140
Early research (Phase 1)Active Not RecruitingNCT06193993
What this trial is testing

Effect of Low-dose 500 mg Abiraterone Acetate in Treatment of Metastatic Prostate Cancer Patients

Who this might be right for
Prostate CancerMetastatic CancerHormone Sensitive Prostate Cancer+1 more
National University Hospital, Singapore 10
Post-approval studies (Phase 4)Active Not RecruitingNCT06479187
What this trial is testing

PSMAtrack-tracking Changes in PSMA-PET During Initial Therapy for Metastatic Hormone-sensitive Prostate Cancer

Who this might be right for
Metastatic Prostate CancerHormone Sensitive Prostate CancerMetastatic Hormone-sensitive Prostate Cancer (mHSPC)
Brigham and Women's Hospital 20
Not applicableLooking for participantsNCT07181122
What this trial is testing

Quality of Life, Functional and Cognitive Outcomes in Patients With Metastatic Hormone-Sensitive Prostate Cancer

Who this might be right for
Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Ankara Etlik City Hospital 102
Large-scale testing (Phase 3)Active Not RecruitingNCT04076059
What this trial is testing

An Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Chinese Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)

Who this might be right for
Metastatic Hormone Sensitive Prostate Cancer
Astellas Pharma China, Inc. 180
Load More Results